These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 944394)

  • 21. [Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism].
    Truelle JL; Chanelet J; Bastard J; Six P; Emile J
    Sem Hop Ther; 1977 Nov; 53(9):453-6. PubMed ID: 341320
    [No Abstract]   [Full Text] [Related]  

  • 22. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N; Maurin B; Puma C; Chezaubernard C; Morain P; Baunez C; Nieoullon A; Amalric M
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of Parkinson's disease: use of piribedil].
    Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(1):54-6. PubMed ID: 14870695
    [No Abstract]   [Full Text] [Related]  

  • 25. [Considerations in the drug treatment of parkinsonism (author's transl)].
    Hungerbühler JP; Regli F
    Schweiz Rundsch Med Prax; 1978 Nov; 67(45):1648-57. PubMed ID: 30976
    [No Abstract]   [Full Text] [Related]  

  • 26. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Sonninen V; Marttila R
    Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delusional infestation induced by piribedil add-on in Parkinson's disease.
    Kölle M; Lepping P; Kassubek J; Schönfeldt-Lecuona C; Freudenmann RW
    Pharmacopsychiatry; 2010 Aug; 43(6):240-2. PubMed ID: 20614418
    [No Abstract]   [Full Text] [Related]  

  • 28. Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
    Birket-Smith E
    Acta Neurol Scand; 1975 Aug; 52(2):158-60. PubMed ID: 1155032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
    Emile J; Chanelet J; Truelle JL; Bastard J
    Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
    [No Abstract]   [Full Text] [Related]  

  • 30. [Modern aproaches to the treatment of early stages of Parkinson disease].
    Artem'ev DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):55-9. PubMed ID: 16329637
    [No Abstract]   [Full Text] [Related]  

  • 31. Dopamine receptor stimulation in the treatment of depression: piribedil (ET-495).
    Shopsin B; Gershon S
    Neuropsychobiology; 1978; 4(1):1-14. PubMed ID: 622219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA; Tel BC; Jackson MJ; Hansard MJ; Braceras R; Bonhomme C; Chezaubernard C; Del Signore S; Rose S; Jenner P
    Mov Disord; 2002 Sep; 17(5):887-901. PubMed ID: 12360537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.
    Perez-Lloret S; Rascol O
    CNS Drugs; 2016 Aug; 30(8):703-17. PubMed ID: 27344665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Initial treatment of Parkinson's disease].
    Kulisevsky J; López-Villegas D
    Rev Neurol; 1997 Aug; 25 Suppl 2():S163-9. PubMed ID: 9280684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the management of parkinson's disease.
    Marsden CD
    Scott Med J; 1976 Jul; 21(3):139-48. PubMed ID: 781839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New therapeutic indications for a dopamine antagonist, Piribedyl].
    Schmitt H; Laubie M; Poignant JC; Krikorian A; Evrard Y; Freyria JL; Arnaud F
    Sem Hop; 1978 Mar; 54(5-8):325-34. PubMed ID: 211628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1986 Jun; 28(716):62-4. PubMed ID: 3713639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.